Yubiao Guo

机构：Sun Yat-sen University, First Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital, Sun Yat-sen University, State Key Laboratory of Respiratory Disease, Guangzhou Medical University · ORCID：0000-0003-3153-8121

发表论文 117 篇 · 总被引 2519 次 · h-index 22

代表论文

• Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant (2024 · JAMA · 被引 187)
• First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial (2024 · Med · 被引 18)
• GLUT1 mediates the release of HMGB1 from airway epithelial cells in mixed granulocytic asthma (2024 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 被引 14)
• Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK ‐positive NSCLC from a phase II study (2024 · 癌症：英文版 · 被引 10)
• GLUT1 contributes to impaired epithelial tight junction in the late phase of acute lung injury (2023 · European Journal of Pharmacology · 被引 10)
• Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET -amplification ( MET amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study. (2025 · Journal of Clinical Oncology · 被引 9)